Company
Nova Mentis Life Science Corp
Headquarters: Vancouver, BC, Canada
CEO: Mr. William Rascan
Market Cap
C$2.9 Million
CAD as of Jan. 1, 2024
US$2.2 Million
Nova Mentis Life Science Corp Categories
Canada Healthcare Drug Manufacturers—Specialty & GenericCanada Healthcare Canada Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Nova Mentis Life Science Corp., through its subsidiaries, engages in the research and development of medicinal psychedelics for neuroinflammatory conditions with a focus on autism spectrum disorder in Canada. It is also involved in the research and development of psychedelic medicines for metabolic indications, such as obesity and diabetes; and development of cannabis products. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is headquartered in Vancouver, Canada.
Top 1-year algo backtest: +191.38%
$10,000 in June 2023 would now be $29,138 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Nova Mentis Life Science Corp has the following listings and related stock indices.
Stock: CSE: NOVA wb_incandescent
Stock: FSX: HN3Q wb_incandescent